RSI Near Rock Bottom, and the Third Insider Steps In

ISB Research · Favorable · sent to Ultimate members October 7, 2026

AgomAb is a clinical-stage biotech working on oral and inhaled drugs for Crohn's and other inflammatory diseases, and the finance chief just added $85,940 at $8.59. He's a repeat buyer, and he's the third insider to step in here in the last 30 days. The stock sits near the bottom of its yearly range, down more than 50% from its high, which is the kind of washout that tends to bounce for a month before fading, so time your patience accordingly. Every timeframe still reads sell and healthcare has been one of the weaker corners of this tape, so this is a contrarian lean on a CFO who keeps writing checks, not a clean trend.

Ultimate members received this analysis in real time.